World Melanoma Day Global Symposium

OncoDiscovery Award - A New Short-Term Funding Opportunity for Early-Career Medical Oncologists Around the World

Sigmund Freud’s Last Decision: The Philosophy Behind His Final Act

How I Treat Bladder Cancer in 2026: OncoDaily Virtual Summit

Grand Rounds by OncoDaily: AI in Oncology Edition

Life of a Young Oncologist: Balancing Hope And Home

FDA Greenlit New Pancreatic Cancer Drug Daraxonrasib For Expanded Access

OncoDaily at ASCO 2026

Calculators

Body Mass Index (BMI)

Cockcroft-Gault Creatinine Clearance Calculator

BSA Calculator – Body Surface Area

Carboplatin Dose Calculator (Calvert Formula)

Child-Pugh Score Calculator

ECOG Score Calculator

IBW / Adjusted Body Weight (Devine Formula)

Bone Scan Index (BSI) Tracker

Khorana Score (Cancer-Associated VTE Risk)

MASCC Risk Index Calculator (Febrile Neutropenia)

IMDC Risk Score Calculator (Metastatic RCC)

Oncotype DX Recurrence Score (RS) Categorizer

Cisplatin Cumulative Dose Toxicity Tracker

CTCAE v6.0 Adverse Events Grader

Grade adverse events based on CTCAE v6.0 criteria. Select an adverse event and enter the lab value or clinical finding to determine the severity grade (1-5).

Enter the lab value or clinical finding

CTCAE v6.0 Grade Scale:

  • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
  • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL.
  • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
  • Grade 4: Life-threatening consequences; urgent intervention indicated.
  • Grade 5: Death related to AE.